European Commission approves label expansion of Roche ’s Hemlibra to include people with moderate haemophilia A in the EU
Hemlibra, already approved for severe haemophilia A in the EU, will now also provide an effective and convenient prophylactic treatment option for people with moderate haemophilia AModerate haemophilia A can have a significant impact on the lives of people affected, with only 15% living a bleed-free life1The approval is based on the HAVEN 6 results, whereHemlibra demonstrated effective bleed control and a favourable safety profile in people with moderate haemophilia A without inhibitors2Basel, 01 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission approved the expansion of the He...
Source: Roche Investor Update - February 1, 2023 Category: Pharmaceuticals Source Type: news

Coding changes that will impact radiology practices in 2023
In a new column, Erin Stephens of Healthcare Administrative Partners (HAP) review...Read more on AuntMinnie.com
Source: AuntMinnie.com Headlines - January 31, 2023 Category: Radiology Source Type: news

New wizard for submitting mRNA sequences to GenBank
Do you submit eukaryotic nuclear mRNA sequences to GenBank? A new mRNA submission wizard is available! Built on the modern Submission Portal framework, this new wizard will bring you an enhanced experience, including:   Guided submission experience specific for mRNA sequences  Automated trimming of vector and removal of short sequences   Easier input for source metadata  … Continue reading New wizard for submitting mRNA sequences to GenBank →
Source: NCBI Insights - January 30, 2023 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New Bankit Coding sequences (CDS) FASTA GenBank mRNA Submissions Portal Source Type: news

The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are. That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Study Comparing Data from Hospitals and Insurers Finds Major Hospitals Still Not Complying with Price Transparency Law
But insurers are complying under the Transparency in Coverage regulations and that is where discrepancies in the disclosure of prices to the public have been found Despite federal regulations requiring hospitals to publicly post their prices in advance of patient services, some large health systems still do not follow the law. That’s according to a […] The post <strong>Study Comparing Data from Hospitals and Insurers Finds Major Hospitals Still Not Complying with Price Transparency Law</strong> appeared first on Dark Daily.
Source: Dark Daily - January 25, 2023 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Coding, Billing, and Collections Compliance, Legal, and Malpractice Laboratory Management and Operations Laboratory News Laboratory Testing anatomic pathology Ascension Health centers for medicare and medicaid services clinical laboratory Source Type: news

Coding issues of open-ended questions in a cross-cultural context - Scholz E, Dorer B, Zuell C.
Although cross-cultural surveys increasingly use open-ended questions to obtain detailed information on respondents' attitudes, the issue of coding quality is rarely addressed. These questions are always challenging but even more so in multilingual, cross-...
Source: SafetyLit - January 24, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Yuga Labs blacklists Blur, SudoSwap and other marketplaces in Sewer Pass mint
Yuga Labs blacklisted at least four marketplaces that don't mandate NFT royalties in its newest NFT drop, Sewer Pass. Sewer Pass includes coding that blocks NFT transactions from wallets belonging to Blur, SudoSwap, LooksRare and NFTX, according to Simon Cousaert, The Block Research's Director of…#qql #nftx #simoncousaert #blursudoswap #nft #blockresearch #blockcryptoinc #looksrare #x2y2 #ethfourhours
Source: Reuters: Health - January 18, 2023 Category: Consumer Health News Source Type: news

What Are Common Dietary Fermentable Carbohydrates?
Discussion Parents may often come to the pediatrician for concerns about crying and colic, increased belching, abdominal distention, increased flatulence, abdominal pain or stool changes. They complain of increased “gassiness,” which could mean any or a combination of these problems, or something different that they believe is referred to the abdomen. In newborns parents’ intolerance for crying and normal changes in the abdomen (e.g. appearing larger or smaller) may have them complain of “gassiness” but they do not mean actual belching or flatulence. In older children, parents may state that t...
Source: PediatricEducation.org - January 16, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

As it shifts focus from DIY computer kits, Kano spins out its creative software suite as a standalone business
Kano Computing (“Kano”), the venture-backed company best known for its DIY computer kits and software for teaching coding and STEM skills to kids, is spinning out its creative software suite and online community platform as an independent business. The move comes as the U.K. company has been…#dotsch #kanocodeandmakeart #harrypotter #alexklein #kanocomputings #stemplayer #disney #raspberrypibased #markzuckerberg #code
Source: Reuters: Health - January 12, 2023 Category: Consumer Health News Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news

Exploring challenges and mitigation strategies towards practicing Teledentistry
Conclusion Teledentists face Personnel, Technological and Organizational challenges and related potential solutions from those practicing Teledentistry in Pakistan. Government should encourage Teledentistry to reduce long-term costs, encourage preventive services and enable rural access to dental care. They should also involve all stakeholders to develop regulations for practicing Teledentistry in Pakistan.
Source: Dental Technology Blog - January 11, 2023 Category: Dentistry Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20